Ambit Scraps IPO, Adds $30M in VC Round for AC220 Study
By Jennifer Boggs
Monday, June 13, 2011
Ambit Biosciences Inc.'s venture syndicate stepped up for a $30 million Series D-2 round to help support the ongoing Phase II pivotal trial of acute myeloid leukemia (AML) drug AC220 and allow the San Diego-based biotech to avoid the less-than-friendly initial public offering (IPO) market.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.